Search results for "ECK"

showing 10 items of 2091 documents

Factors influencing serum 25-hydroxivitamin D levels and other bone metabolism parameters in healthy older women

2016

Objective: Older women have frequently low serum 25-hydroxivitamin D (25[OH]D) concentrations, high parathormone (PTH) levels and low bone mineral density (BMD) values. Endogenous synthesis, dietary habits, sunlight exposure and fat-mass-mediated storage may influence 25(OH)D levels and bone metabolism, but the relevance of these factors in the elderly has yet to be fully elucidated. We aimed to investigate the influence of dietary vitamin D intake and fat mass on serum 25(OH)D levels and bone metabolism in older women. Design: Cross-sectional. Setting: Community. Participants: 218 fit older women attending a biweekly mild fitness program. Measurements: Dietary habits was investigated throu…

0301 basic medicinemedicine.medical_specialtyBone densityMedicine (miscellaneous)030209 endocrinology & metabolism25-hydroxyvitamin D; bone metabolism; dietary vitamin D intake; elderly; fat mass; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and Gerontologydietary vitamin D intakeelderlyNOBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineVitamin D and neurologyFemoral neckBone mineralHyperparathyroidism030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryfat massmedicine.disease25-hydroxyvitamin Dmedicine.anatomical_structureEndocrinologychemistry25-hydroxyvitamin D dietary vitamin D intake fat mass bone metabolism elderlyCalcifediolSecondary hyperparathyroidismbone metabolismGeriatrics and GerontologybusinessThe journal of nutrition, health & aging
researchProduct

Treatment challenges in and outside a network setting: Head and neck cancers.

2019

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lea…

0301 basic medicinemedicine.medical_specialtySocio-culturaleSocial issuesMultidisciplinary team03 medical and health sciencesTherapeutic approach0302 clinical medicineRare DiseasesMultidisciplinary approachmedicineHumansAdverse effectIntensive care medicineHead and neck cancerReferral and ConsultationPatient Care TeamEuropean reference networks joint action of rare cancers ; Head and neck cancer ; Multidisciplinary team ; Rare diseasebusiness.industryHead and Neck NeoplasmHead and neck cancerEuropean reference networks joint action of rare cancersGeneral MedicineMultidisciplinary teammedicine.diseaseEurope030104 developmental biologyClinical researchOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisEuropean reference networks joint action of rare cancerSurgerybusinessEuropean reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease; Surgery; OncologyRare diseaseDelivery of Health CareRare diseaseHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

“New Kids on the Block” — The Game Changers. The Role of Immune Check Point Blockade in Personalised Treatment of Prostate, Urinary Bladder and Kidne…

2021

Abstract Early detection and diagnosis of cancer followed by a personalised approach to treatment is a key and can save lives. It has been an important issue in both the medical and social fields. The search for instruments and/or diagnostics tools able to detect cancers at an early stage has led to consideration of the usage of various approaches, such as exhaled air, biomarkers in blood, urine testing as well as imaging techniques. This actual time and everything that is happening around us could be characterised as a strange and very unpredictable time. This comparison could be made not only due to the actual coronavirus situation, but also the same can be noticed in the personalised med…

0301 basic medicinemedicine.medical_specialtyUrinary bladderbusiness.industryUrologymedicine.diseaseBlockade03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmune systemProstate030220 oncology & carcinogenesisBlock (telecommunications)medicinebusinessKidney cancerCheck pointProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

2019

Abstract Background ABBV-181 is a humanized anti-PD1 monoclonal antibody; dose finding and early safety, PK and pharmacodynamic data have been reported (ESMO18). This report summarizes data from the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts in the Ph1 FIH study (NCT03000257). Methods Patients (pts) with previously treated, advanced HNSCC and NSCLC received ABBV-181 IV, 250 mg Q2W or 500 mg Q4W to progression. Response was assessed by RECIST v1.1 and iRECIST. Results As of April 2019, 81 pts were dosed. Table . 1288P n (%) HNSCC n = 41 NSCLC n = 40 Median days on treatment, range 72, 1–407 71, 1–421 Dose: 250 mg/500 mg 31/10 19/21 …

0301 basic medicinemedicine.medical_specialtybusiness.industryAnti pd 1Physical healthStock optionsHematology03 medical and health sciencesNeoplasm progressionDose finding030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePartial responseMedicinemedicine.symptombusinessHead and neck carcinomaConfusionAnnals of Oncology
researchProduct

Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease

1992

SummaryThis paper is an up-dated review of the role of systemic chemotherapy in the management of recurrent and/or metastatic head and neck carcinoma.

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyAntineoplastic AgentsDiseaseHead neck cancer03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Head and neckHead and neck carcinomaPharmacologyChemotherapybusiness.industrySystemic chemotherapyHead and neck cancerAdvanced stagemedicine.diseaseSurgeryInfectious DiseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisRadiologyNeoplasm Recurrence Localbusiness
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Immunotherapeutic properties of chemotherapy

2017

IF 5.363; International audience; Impressive remissions driven by immunological checkpoint blockade in cancer patients have prompted the scientific community to investigate afresh the crosstalk between cancer cells and the patient's immune system. Preclinical and clinical studies have highlighted that the anticancer efficacy of some conventional chemotherapeutics is based on their ability to restore anticancer immune responses. The current challenge is to understand and circumvent immune resistance mechanisms to chemo- and immunotherapies to design relevant immunotherapy and chemotherapy combinations. In this review, we will summarize which immunological processes are involved in the antica…

0301 basic medicinemedicine.medical_treatmentAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesImmune systemNeoplasmsDrug DiscoveryAnimalsHumansMedicineCytotoxicityPharmacologyChemotherapybusiness.industryImmunogenicityImmunotherapyImmune checkpointGastrointestinal Microbiome3. Good healthBlockade030104 developmental biologyImmunologyCancer cellCancer researchImmunotherapybusinessCurrent Opinion in Pharmacology
researchProduct

Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia

2020

Background. Haematological and non-haematological malignancies are able to escape the host immune by the capacity to hijack the immune check-points. Several immune check-point molecules are known, such as T cell immunoglobulin mucin-3 (TIM-3), cytotoxic T-cell antigen-4 (CTLA-4), programmed death-1 (PD-1) with its ligand PD-L1 and others.1 The function of these immune check-points is to prevent the damage resulting from an excessive activation of the immune response in the setting of chronic antigenic stimulation, thus leading to autoimmune phenomena, as proved in knock-out mice models. PD-1 is normally present on activated T lymphocytes membrane, acting as a negative costimulatory receptor…

0301 basic medicinemedicine.medical_treatmentvirusesanimal diseaseschemical and pharmacologic phenomena03 medical and health sciences0302 clinical medicinePD-L1Medicinebiologybusiness.industrylcsh:RC633-647.5Myeloid leukemiaHematologyImmunotherapylcsh:Diseases of the blood and blood-forming organsAcute myeloid leukemia Immune check-point blockade Immunotherapy PD-1 PD-L1biochemical phenomena metabolism and nutritionacute myeloid leukemia; immune check-point blockade; PD-1; PD-L1; immunotherapy030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchbiology.proteinbacteriaBone marrowbusinessHematology Reports
researchProduct

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

2017

ObjectiveCancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.DesignTo discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein mic…

0301 basic medicinep53DNA ReplicationCELL CYCLE CONTROLDNA damageColorectal cancerColonmedicine.medical_treatmentAntineoplastic AgentsBiologyBioinformaticsmedicine.disease_causeDNA DAMAGETargeted therapy03 medical and health sciencesCancer stem cellCell Line TumormedicineHumansCHEK11506DRUG DEVELOPMENTOligonucleotide Array Sequence AnalysisMutationCOLORECTAL CANCERSettore MED/06 - ONCOLOGIA MEDICAGastroenterologyCHEMOTHERAPYmedicine.diseaseImmunohistochemistryPrexasertib030104 developmental biologyPyrazinesCheckpoint Kinase 1MutationCancer researchNeoplastic Stem CellsPyrazolesStem cellTumor Suppressor Protein p53Colorectal NeoplasmsGut
researchProduct

Inoculation of Torulaspora delbrueckii as a bio-protection agent in winemaking

2018

International audience; In oenology, bio-protection consists in adding bacteria, yeasts or a mixture of microorganisms on grape must before fermentation in order to reduce the use of chemical compounds such as sulphites. More particularly, non-Saccharvinyces yeasts are used as a total or partial alternative to sulphites. However, scientific data capable of proving the effectiveness of adding these yeasts on grape must is lacking. This study reports the analysis of antimicrobial and antioxidant effects of one non-Saccharamyces yeast, Torulaspora delbruecicii, inoculated at the beginning of the white winemaldng process in two Burgundian wineries as an alternative to sulphiting. The implantati…

0301 basic medicinesulfur-dioxideMicroorganism030106 microbiologyTorulaspora delbrueckiiwhite winesWinechardonnay winesAntioxidants03 medical and health sciencesTorulaspora delbrueckiialcoholic fermentationOxidation[SDV.IDA]Life Sciences [q-bio]/Food engineeringVitisFood sciencecerevisiaeOenologyWinemakingWinebiologyChemistrysequential inoculationfood and beveragesTorulasporaWine bio-protectionribosomal-rna genenon-saccharomyces yeastsbiology.organism_classificationAntimicrobialYeastwine fermentationNon-Saccharomyces yeastFermentationFood MicrobiologyFermentationmixed culturesAlternative to sulphitesFood ScienceFood Research International
researchProduct